Table 1.
Patient sample by IBD type
| Patient characteristics | CD n = 6917 | UC n = 6118 | Unclassified n = 553 | Total N = 13,588 | P |
|---|---|---|---|---|---|
|
Years in IBD registrya Median (Min–Max) 25th; 75th percentiles |
9 (0–19) 4; 15 |
11 (0–19) 5; 17 |
8 (0–19) 4; 13 |
10 (0–19) 5; 15 |
< 0.001 |
|
Age: Mean (SD)Median (Min–Max) Median (Min–Max) 25th;75th percentiles |
45.9 (15.9) 44.7 (19–100) 33.0; 56.4 |
52.1 (16.7) 51.2 (19–101) 39.4; 64.3 |
51.5 (18.0) 49.8 (19–102) 37.0; 64.5 |
48.9 (16.6) 47.8 (19–102) 35.7; 60.7 |
< 0.001 |
| Age groups: | < 0.001 | ||||
| 18–45 | 3512 (50.8) | 2155 (35.2) | 206 (37.3) | 5873 (43.2) | |
| > 45–65 | 2422 (35.0) | 2493 (40.8) | 212 (38.3) | 5127 (37.7) | |
| Over 65 | 983 (14.2) | 1470 (24.0) | 135 (24.4) | 2588 (19.1) | |
| Sex: | < 0.001 | ||||
| Female | 3381 (48.9) | 3167 (51.8) | 315 (57.0) | 6863 (50.5) | |
| Male | 3536 (51.1) | 2951 (48.2) | 238 (43.0) | 6725 (49.5) | |
| Biologic treatmentb | < 0.001 | ||||
| Yes | 2538 (36.7) | 742 (12.1) | 88 (15.9) | 3368 (24.8) | |
| No (never) | 4379 (63.3) | 5376 (87.9) | 465 (84.1) | 10,220 (75.2) | |
| SES | 0.769 | ||||
| 1 to 5 (low) | 1685 (24.4) | 1443 (23.6) | 132 (23.9) | 3260 (24.0) | |
| 6 to 7 (moderate) | 2610 (37.7) | 2355 (38.5) | 211 (38.2) | 5176 (38.2) | |
| 8 to 10 (high) | 2606 (37.7) | 2305 (37.7) | 207 (37.4) | 5118 (37.8) | |
| Missing | 16 (0.2) | 15 (0.2) | 3 (0.5) | 34 (0.9) |
Values are n (column %) unless noted otherwise. P-values for statistically significant differences were estimated using Chi-square tests for comparisons of categorical data and analysis of variance for comparisons of continuous data
aYear of inclusion in the IBD registry at the start of 2019. Zero represents less than 1 year within the registry
bBiologic and small molecules treatment was defined as having purchased at least one biologic medication including: Vedolizumab, Infliximab, Adalimumab, Ustekinumab, Golimumab, Tofacitinib, or Certolizumab
CD Crohn's disease; UC Ulcerative Colitis; IQR inter quartile range; SD standard deviation; SES socioeconomic status